4570 — Immuno-Biological Laboratories Co Cashflow Statement
0.000.00%
Last trade - 00:00- ¥29bn
- ¥28bn
- ¥970m
Annual cashflow statement for Immuno-Biological Laboratories Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -311 | -250 | -281 | 125 | 210 |
| Depreciation | |||||
| Non-Cash Items | 86.7 | 134 | 349 | -7.84 | 2.9 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 29.8 | 22.5 | 11 | 14.6 | -44.7 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -194 | -93.2 | 79.7 | 134 | 183 |
| Capital Expenditures | -13.5 | — | — | -18.7 | -59.7 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -3.77 | -156 | 30 | -5.84 | 6 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -17.2 | -156 | 30 | -24.5 | -53.7 |
| Financing Cash Flow Items | -200 | — | -0.001 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -216 | 144 | 0.991 | 0.992 | -31.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -422 | -103 | 113 | 113 | 95.6 |